PBT-1033

PBT-1033 is a zinc and copper ionophore.¹ It induces the uptake of zinc, copper, and iron in M17 neuroblastoma cells when used at concentrations ranging from 2 to 10 µM.² PBT-1033 inhibits phosphorylation of GSK3α and GSK3β in a zinc- and copper-dependent manner and prevents the formation of extracellular protease-resistent amyloid-β (Aβ)-zinc aggregates.³ It increases dendritic spine density in the hippocampus of 4-month- and 14-month-old female Tg2576 mice, which overexpress mutant amyloid precursor protein (APP), when administered at 30 mg/kg per day for 11 days.¹ PBT-1033 (30 mg/kg per day) also reduces the latency to escape during acquisition and after 24 hours in APP/PS1 transgenic mice in a model of Alzheimer’s disease.²

WARNING This product is not for human or veterinary use.

1. Adlard, P.A., Bica, L., White, A.R., et al. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer’s disease. PLoS One 6(3), e17669 (2011).

2. Adlard, P.A., Cherny, R.A., Finkelstein, D.I., et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron. 59(1), 43-55 (2008).

3. Crouch, P.J., Savva, M.S., Hung, L.W., et al. The Alzheimer’s therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. J. Neurochem. 119(1), 220-230 (2011).